Table 4.
Low Risk (n=141) | Medium Risk (n=166) | High Risk (n=63) | p-value* (overall test) | |
---|---|---|---|---|
Count (%) | Count (%) | Count (%) | ||
Age (years) | ---------- | |||
<1 | 5 ( 4%) | 5 ( 3%) | ||
1–9 | 109 (77%) | 146 (88%) | ||
10+ | 27 (19%) | 15 ( 9%) | 63 (100%) | |
Stage | <0.001 | |||
1 | 24 (17%) | 8 ( 5%) | 3 ( 5%) | |
2 | 70 (50%) | 28 (17%) | 6 (10%) | |
3 | 47 (33%) | 130 (78%) | 54 (86%) | |
Group | 0.3 | |||
I | 7 ( 5%) | 4 ( 2%) | 1 ( 2%) | |
II | 16 (11%) | 11 ( 7%) | 5 ( 8%) | |
III | 118 (84%) | 151 (91%) | 57 (90%) | |
Primary Site | ---------- | |||
Extremity | 26 (18%) | 29 (17%) | 13 (21%) | |
GU/BP | 56 (40%) | 6 (10%) | ||
Parameningeal | 28 (20%) | 78 (47%) | 34 (54%) | |
Retroperitoneal/Perineal | 1 ( 1%) | 44 (27%) | 4 ( 6%) | |
Other | 30 (21%) | 15 ( 9%) | 6 (10%) | |
Tumor Size | ---------- | |||
≤ 5 cm | 103 (73%) | 34 (20%) | 9 (14%) | |
>5 cm | 38 (27%) | 132 (80%) | 54 (86%) | |
Tumor Invasion | <0.001 | |||
T-1 | 85 (60%) | 65 (39%) | 22 (35%) | |
T-2 | 56 (40%) | 101 (61%) | 41 (65%) | |
Regional Lymph Nodes | <0.001 | |||
N-0 | 125 (89%) | 142 (86%) | 42 (67%) | |
N-1 | 16 (11%) | 24 (14%) | 21 (33%) | |
Histology | <0.001 | |||
Embryonal | 70 (50%) | 100 (60%) | 13 (21%) | |
Alveolar | 59 (42%) | 58 (35%) | 42 (67%) | |
Undifferentiated | 0 | 5 ( 3%) | 3 ( 5%) | |
RMS, NOS | 12 ( 9%) | 3 ( 2%) | 5 ( 8%) | |
Strata | <0.001 | |||
Embryonal Stage 2/3 Group III | 70 (50%) | 74 (45%) | 13 (21%) | |
ALV/UDS Stage 1 or Group I | 27 (19%) | 11 ( 7%) | 3 ( 5%) | |
ALV/UDS other | 34 (24%) | 42 (25%) | 32 (51%) | |
PM with extension | 10 ( 7%) | 39 (23%) | 15 (24%) |
Distributions were compared among groups using a Chi-square test or Fisher’s exact test. No formal comparison was made for factors involving age, maximum diameter, and primary site, which were used directly in the risk group definitions.